Analytical Data
-
基因名
CHM
- Application
-
别名
CHM；CHMI；LECT1；MYETS1；Leukocyte cell-derived chemotaxin 1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P24386
-
表达区间
1-653aa
-
氨基酸序列
MADTLPSEFDVIVIGTGLPESIIAAACSRSGRRVLHVDSRSYYGGNWASFSFSGLLSWLKEYQENSDIVSDSPVWQDQILENEEAIALSRKDKTIQHVEVFCYASQDLHEDVEEAGALQKNHALVTSANSTEAADSAFLPTEDESLSTMSCEMLTEQTPSSDPENALEVNGAEVTGEKENHCDDKTCVPSTSAEDMSENVPIAEDTTEQPKKNRITYSQIIKEGRRFNIDLVSKLLYSRGLLIDLLIKSNVSRYAEFKNITRILAFREGRVEQVPCSRADVFNSKQLTMVEKRMLMKFLTFCMEYEKYPDEYKGYEEITFYEYLKTQKLTPNLQYIVMHSIAMTSETASSTIDGLKATKNFLHCLGRYGNTPFLFPLYGQGELPQCFCRMCAVFGGIYCLRHSVQCLVVDKESRKCKAIIDQFGQRIISEHFLVEDSYFPENMCSRVQYRQISRAVLITDRSVLKTDSDQQISILTVPAEEPGTFAVRVIELCSSTMTCMKGTYLVHLTCTSSKTAREDLESVVQKLFVPYTEMEIENEQVEKPRILWALYFNMRDSSDISRSCYNDLPSNVYVCSGPDCGLGNDNAVKQAETLFQEICPNEDFCPPPPNPEDIILDGDSLQPEASESSAIPEANSETFKESTNLGNLEESSE
-
分子量
77.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on CHM (Choroideremia) recombinant protein is primarily driven by the need to understand and develop therapies for choroideremia, a rare genetic disorder caused by mutations in the CHM gene, which is essential for proper functioning of the retinal cells. This progressive condition leads to vision loss due to the degeneration of the retinal pigment epithelium and photoreceptor cells. The study of CHM recombinant protein focuses on the production and characterization of the protein encoded by the CHM gene, allowing researchers to explore its biological functions and interactions within cellular pathways. Advances in recombinant DNA technology have facilitated the expression of this protein in model systems, offering insights into its role in cellular processes such as photoreceptor maintenance and survival. Furthermore, understanding the structure and function of CHM recombinant protein is crucial for the development of potential gene therapies, including gene replacement strategies that aim to restore normal function in affected individuals. These research efforts are complemented by the use of animal models and patient-derived cells, which provide an avenue for investigating the effects of CHM mutations and the efficacy of emerging therapeutic approaches. Overall, the study of CHM recombinant protein not only enhances our understanding of choroideremia but also contributes to the broader field of retinal disorders, paving the way for innovative treatments to combat vision loss.
